● Recruiting

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis · Sponsor: Insmed Gene Therapy LLC

PhasePhase 1

Planned participants23

Who can joinAll sexes, 18 Years to 79 Years

Healthy volunteersNo

About this study

The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.

This description comes directly from the study's public registry record.

Talk to the study team

Insmed Medical Information · 1-844-446-7633 · medicalinformation@insmed.com

Always discuss trial participation with your own doctor first.

Locations (5)

USA004	La Jolla, California, United States	Recruiting
USA002	Palo Alto, California, United States	Recruiting
USA001	Columbia, Missouri, United States	Recruiting
USA007	Columbus, Ohio, United States	Recruiting
USA006	Philadelphia, Pennsylvania, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07290062